Why did Labcorp (LH) stock move recently?

On 7/23/2026, Labcorp moved +3.4% — Labcorp shares rose as investors anticipated strong Q2 earnings growth ahead of the July 30 report, supported by ongoing diagnostics and biopharma demand momentum from recent results. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Labcorp (LH) overvalued or fairly valued?

MarketChacha shows Labcorp's valuation in context — a trailing P/E of about 25.2, a forward P/E of about 16.5, a price-to-book of about 3.1 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Labcorp's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (2.23×) from reported figures — education, not a rating.

What is Labcorp's revenue?

Labcorp reported revenue of $14.0B for FY2025, with net profit of $876.5M, per official filings.

What is the share price of Labcorp (LH)?

Labcorp last traded at $326.89 (-1.4% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

Labcorp

LH · NYSE · Healthcare · United States

Snapshot

TickerLH

ExchangeNYSE

SectorHealthcare

IndustryDiagnostics & Research

CountryUnited States

Employees71,000

HeadquartersBurlington, United States

Websitewww.labcorp.com

Filings tracked25

About Labcorp

Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics; a strategic alliance with the National Association of Community Health Centers to support current and emerging clinical leaders through the NACHC Leadership Exchange for Chief Medical Officers; and Alliance for Clinical Trials in Oncology to advance national clinical trial for patients diagnosed with colorectal cancer. The company was founded in 1995 and is headquartered in Burlington, North Carolina.

Who owns it

Insiders0.3%
Institutions99.7%
Public & other0.0%

1,437 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.8.11%
Vanguard Capital Management LLC6.61%
Victory Capital Management Inc.5.96%
State Street Corporation4.82%
Vanguard Portfolio Management LLC4.54%
Boston Partners3.76%
Allspring Global Investments Holdings, LLC2.76%
Geode Capital Management, LLC2.70%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion2.23×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend3.4% → 6.3%

Margin has expanded by about 2.8 points — the business is getting more profitable.

Growth qualityrev 7% · PAT 45%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $3.7B · EPS 4.45

Est. earnings growth +9.3%

Next fiscal year

Rev $15.5B · EPS 19.82

Est. earnings growth +8.0%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$14.0B

Net margin

6.3%

ROE

10.2%

Revenue CAGR (2y)

+7.1%

Profit CAGR (2y)

+44.8%

EPS (FY2025)

10.46

Net profit (FY2025)

$876.5M

Ask MarketChacha about LH

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Jul 23, 2026
Labcorp shares rose as investors anticipated strong Q2 earnings growth ahead of the July 30 report, supported by ongoing diagnostics and biopharma demand momentum from recent results.
source 1 ↗source 2 ↗· confidence: medium

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$14.0B	$876.5M	10.46	6.3%	10.2%
FY2024	$13.0B	$746.0M	8.84	5.7%	9.3%
FY2023	$12.2B	$418.0M	4.77	3.4%	5.3%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$3.7B	$298.7M	3.64	8.0%
2026Q1	$3.5B	$277.8M	3.35	7.9%
2025Q3	$3.6B	$261.1M	3.12	7.3%
2025Q2	$3.5B	$237.9M	2.84	6.7%
2025Q1	$3.3B	$212.8M	2.52	6.4%
2024Q3	$3.3B	$169.3M	2.00	5.2%
2024Q2	$3.2B	$205.3M	2.43	6.4%
2024Q1	$3.2B	$228.0M	2.69	7.2%
2023Q3	$3.1B	$183.3M	2.11	6.0%
2023Q2	$3.0B	$188.9M	2.12	6.2%
2023Q1	$3.0B	$212.9M	2.39	7.0%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

10-Q filing
SEC8/5/2026
8-K — Results of operations, Exhibits
SEC7/30/2026material
8-K — Reg FD disclosure, Exhibits
SEC7/10/2026material
8-K — Reg FD disclosure, Exhibits
SEC6/30/2026material
8-K — Reg FD disclosure, Exhibits
SEC5/27/2026material
8-K — Shareholder vote results
SEC5/26/2026material
10-Q filing
SEC5/4/2026
8-K — Results of operations, Exhibits
SEC4/30/2026material
8-K — Reg FD disclosure, Exhibits
SEC4/9/2026material
8-K — Reg FD disclosure, Exhibits
SEC3/31/2026material
8-K — Material agreement, Material financial obligation, Exhibits
SEC3/20/2026material
10-K filing
SEC2/24/2026
8-K — Results of operations, Exhibits
SEC2/17/2026material
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC2/9/2026material
8-K — Material agreement, Material financial obligation, Exhibits
SEC1/29/2026material
8-K — Reg FD disclosure, Exhibits
SEC1/15/2026material
8-K — Reg FD disclosure, Exhibits
SEC1/14/2026material

2025

8-K — Reg FD disclosure, Exhibits
SEC12/30/2025material
8-K — Executive/director change
SEC12/15/2025material
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC12/10/2025material
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC11/24/2025material
10-Q filing
SEC10/31/2025
8-K — Results of operations, Exhibits
SEC10/28/2025material
8-K — Reg FD disclosure, Exhibits
SEC10/8/2025material
8-K — Reg FD disclosure, Exhibits
SEC9/25/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.